Bulletin
Investor Alert

Market Pulse Archives

May 20, 2022, 8:15 a.m. EDT

Foghorn's stock drops 23% after FDA puts partial hold on clinical trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Foghorn Therapeutics Inc. (FHTX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Foghorn Therapeutics Inc. /zigman2/quotes/222085286/composite FHTX +2.79% were down 23.7% in premarket trading on Friday, the day after the company said U.S. regulators had placed a partial clinical hold on a Phase 1 clinical trial assessing an experimental therapy for relapsed and/or refractory acute myelogenous leukemia. The Food and Drug Administration has asked for a review of the safety database, as well as information about risk mitigation and clinical activity across doses. Foghorn's stock has declined 49.3% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +1.06% is down 18.1%.

/zigman2/quotes/222085286/composite
US : U.S.: Nasdaq
$ 13.98
+0.38 +2.79%
Volume: 46,278
July 1, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$579.72 million
Rev. per Employee
$41,622
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,825.33
+39.95 +1.06%
Volume: 2.20B
July 1, 2022 5:45p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.